SCHEMBL2097759

SCHEMBL2097759

COCc1sc(-c2ccccc2)nc1C

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.53
PPARD Q03181 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
GAA P10253 1/20 0.47
TP53 P04637 3/20 0.46
TRPM8 Q7Z2W7 1/20 0.46
HPGD P15428 2/20 0.45
NPC1 O15118 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 2/20 0.45
THRB P10828 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097756 0.85 FFAR1 (0.52) FFAR1PPARDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL6002816 0.84 FFAR1 (0.51) FFAR1PPARDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL6840453 0.81 L3MBTL1 (0.55) FFAR1PPARDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL15160329 0.80 PPARD (0.61) FFAR1PPARDALDH1A1MAPTGAA
SCHEMBL1569202 0.79 SMN1; SMN2 (0.53) FFAR1PPARDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3077683 0.79 SMN1; SMN2 (0.56) FFAR1PPARDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL28155818 0.79 SMN1; SMN2 (0.51) FFAR1PPARDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL2413521 0.79 SMN1; SMN2 (0.51) FFAR1PPARDSMN1; SMN2ALDH1A1MAPT
SCHEMBL379217 0.79 SMN1; SMN2 (0.51) FFAR1PPARDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL19936515 0.78 PTGDR2 (0.47) FFAR1SMN1; SMN2ALDH1A1TP53TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 FFAR1 58/4885PPARD 321/4885SMN1; SMN2 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.